4579.T Stock - RaQualia Pharma Inc.
Unlock GoAI Insights for 4579.T
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $3.11B | $1.90B | $2.92B | $2.78B | $1.11B |
| Gross Profit | $2.48B | $1.66B | $2.69B | $2.46B | $969.29M |
| Gross Margin | 79.9% | 87.1% | 92.1% | 88.4% | 87.5% |
| Operating Income | $-213,383,000 | $-337,365,000 | $866.24M | $707.86M | $-486,077,000 |
| Net Income | $-495,031,000 | $-323,662,000 | $723.39M | $755.79M | $-606,985,000 |
| Net Margin | -15.9% | -17.0% | 24.8% | 27.2% | -54.8% |
| EPS | $-22.87 | $-14.98 | $34.50 | $36.07 | $-28.97 |
RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide. Its human products portfolio includes tegoprazan for gastroesophageal reflux disease, which is in phase 1 clinical trial in the United States; and grapiprant for pain management, which is in phase II clinical trial in the United States and phase I clinical trial in China, as well as in phase I clinical trial in China and the United States to treat cancer. The company also provides veterinary products such as, grapiprant for osteoarthritis in dogs; ghrelin receptor agonist to treat cancer-related anorexia/cachexia syndrome, and constipation resulting from spinal cord injury; and ELURA, a drug for the management of weight loss in cats with chronic kidney disease. In addition, it provides TRPM8 blocker for the target indication of neuropathic pain; motilin receptor agonist to treat gastrointestinal dysmotility, including gastroparesis, functional dyspepsia, and post-operative ileus; potassium-competitive acid blocker to treat gastro-esophageal reflux disease that has completed phase 1 clinical trial; 5-HT4 partial agonist to treat gastroparesis, functional dyspepsia, and chronic constipation; 5-HT2B antagonist to treat irritable bowel syndrome with diarrhea; EP4 antagonist, a pain management drugs for dogs; serotonin 5-HT2A and dopamine D2 receptor blocker to treat schizophrenia; EP4 antagonist to treat cancer that is in phase I clinical trial, as well as in phase 1 clinical trial for the indication of pain; Cyclooxygenase-2 inhibitor, Phase I clinical trials for the indication of pain; CB2 agonist; selective sodium channel blocker; P2X7 receptor antagonist, which is in Phase I clinical trials for the target indication of neuropathic pain; and retinoic acid receptor alpha agonist. It has a collaborative agreement with Interprotein Corporation, ASKA Pharmaceutical. Co., Ltd., and Epigeneron, Inc. The company was incorporated in 2008 and is headquartered in Nagoya, Japan.
Visit WebsiteEarnings History & Surprises
4579.TEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 14, 2025 | — | $-8.76 | — | — |
Q2 2025 | May 15, 2025 | — | $-0.24 | — | — |
Q1 2025 | Feb 12, 2025 | — | $-7.16 | — | — |
Q4 2024 | Nov 14, 2024 | — | $-0.74 | — | — |
Q3 2024 | Aug 14, 2024 | — | $-11.36 | — | — |
Q2 2024 | May 15, 2024 | — | $-3.61 | — | — |
Q1 2024 | Feb 14, 2024 | — | $-9.53 | — | — |
Q4 2023 | Nov 10, 2023 | — | $-6.62 | — | — |
Q3 2023 | Aug 10, 2023 | — | $8.04 | — | — |
Q2 2023 | May 15, 2023 | — | $-6.88 | — | — |
Q1 2023 | Feb 14, 2023 | — | $12.21 | — | — |
Q4 2022 | Nov 11, 2022 | — | $-0.11 | — | — |
Q3 2022 | Aug 15, 2022 | — | $28.16 | — | — |
Q2 2022 | May 13, 2022 | — | $-5.77 | — | — |
Q1 2022 | Feb 14, 2022 | — | $27.99 | — | — |
Q4 2021 | Nov 12, 2021 | — | $-6.37 | — | — |
Q3 2021 | Aug 12, 2021 | — | $5.45 | — | — |
Q2 2021 | May 14, 2021 | — | $9.00 | — | — |
Q1 2021 | Feb 12, 2021 | — | $4.38 | — | — |
Q4 2020 | Nov 13, 2020 | — | $-11.42 | — | — |
Latest News
Frequently Asked Questions about 4579.T
What is 4579.T's current stock price?
What is the analyst price target for 4579.T?
What sector is RaQualia Pharma Inc. in?
What is 4579.T's market cap?
Does 4579.T pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to 4579.T for comparison